Search results for "drug delivery."

showing 10 items of 692 documents

Polyhydroxyethylaspartamide-based micelles for ocular drug delivery

2009

In this paper three copolymers of polyhydroxyethylaspartamide (PHEA), bearing in the side chains polyethylene glycol (PEG) and/or hexadecylamine (C(16)) (PHEA-PEG, PHEA-PEG-C(16) and PHEA-C(16) respectively) have been studied as potential colloidal drug carriers for ocular drug delivery. The physical characterization of all three PHEA derivatives, using the Langmuir trough (LT) and micellar affinity capillary electrophoresis (MACE) techniques allowed to assume that whereas alone PHEA backbone is an inert polymer with respect to the interactions with lipid membranes and drug complexation, when PHEA chains are grafted with long alkyl chains like C(16) or in combination C(16) chains and hydrop…

MalePolymersAdministration TopicalBiological AvailabilityPharmaceutical SciencePolyethylene glycolMicelleDexamethasonePermeabilityPolyethylene Glycolschemistry.chemical_compoundocular drug delivery systemIn vivoPEG ratioAnimalsColloidsNetilmicinAminesLipid bilayerMicellesDrug CarriersChromatographyChemistryEpithelium Cornealtechnology industry and agricultureHydrocarbonsBioavailabilityDrug deliverypolymeric micelles amphiphilic copolymersRabbitsPeptidesDrug carrierConjunctiva
researchProduct

Comparison of Active and Passive Targeting of Docetaxel for Prostate Cancer Therapy by HPMA Copolymer–RGDfK Conjugates

2011

N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer-docetaxel-RGDfK conjugate was synthesized, characterized, and evaluated in vitro and in vivo in comparison with untargeted low and high molecular weight HPMA copolymer-docetaxel conjugates. The targeted conjugate was designed to have a hydrodynamic diameter below renal threshold to allow elimination post treatment. All conjugates demonstrated the ability to inhibit the growth of DU145 and PC3 human prostate cancer cells and the HUVEC at low nanomolar concentrations. The targeted conjugate showed active binding to α(v)β(3) integrins in both HUVEC and DU145 cells, whereas the untargeted conjugate demonstrated no evidence of specific binding. …

MalePolymersMice NudePharmaceutical ScienceAntineoplastic AgentsDocetaxelPharmacologyurologic and male genital diseasesArticleMicechemistry.chemical_compoundProstate cancerstomatognathic systemIn vivoCell Line TumorDrug DiscoveryCopolymermedicineAnimalsMethacrylamideCell ProliferationAcrylamidesChemistryProstatic Neoplasmsmedicine.diseaseIn vitroDocetaxelTargeted drug deliveryMolecular MedicineTaxoidsmedicine.drugConjugateMolecular Pharmaceutics
researchProduct

Pre-clinical assessment of a water-in-fluorocarbon emulsion for the treatment of pulmonary vascular diseases

2019

Abstract Hypoxic pulmonary vasoconstriction (HPV) is a well-characterized vascular response to low oxygen pressures and is involved in life-threatening conditions such as high-altitude pulmonary edema (HAPE) and pulmonary arterial hypertension (PAH). While the efficacy of oral therapies can be affected by drug metabolism, or dose-limiting systemic toxicity, inhaled treatment via pressured metered dose inhalers (pMDI) may be an effective, nontoxic, practical alternative. We hypothesized that a stable water-in-perfluorooctyl bromide (PFOB) emulsion that provides solubility in common pMDI propellants, engineered for intrapulmonary delivery of pulmonary vasodilators, reverses HPV during acute h…

MalePulmonary CirculationDrug Evaluation PreclinicalPharmaceutical Science02 engineering and technologyPharmacology030226 pharmacology & pharmacyRats Sprague-DawleyDrug Delivery Systems0302 clinical medicineHypoxic pulmonary vasoconstrictionHigh-altitude pulmonary edemapulmonary hypertensionMedicineFluorocarbonsPhenylpropionatesmedicine.diagnostic_testGeneral Medicine021001 nanoscience & nanotechnologyPulmonary edema3. Good healthPyridazinesTreatment Outcomemedicine.anatomical_structureEmulsions0210 nano-technologyendothelinResearch Articlemedicine.drugpulmonary pressuresAmbrisentanambrisentanHypertension PulmonaryPulmonary Edema03 medical and health sciencesmedicine.arteryAnimalsAntihypertensive AgentsLungsodium nitriteperfluorocarbonbusiness.industrylcsh:RM1-950Watermedicine.diseasePulmonary hypertensionRatsBronchoalveolar lavagelcsh:Therapeutics. PharmacologyPulmonary arteryhigh altitude pulmonary edemabusinessDrug Delivery
researchProduct

Innovative in Vitro Method To Predict Rate and Extent of Drug Delivery to the Brain across the Blood–Brain Barrier

2013

The relevant parameters for predicting rate and extent of access across the blood-brain barrier (BBB) are fu,plasma (unbound fraction in plasma), Vu,brain (distribution volume in brain) and Kp,uu,brain (ratio of free concentrations in plasma and brain). Their estimation still requires animal studies and in vitro low throughput experiments which make difficult the screening of new CNS candidates. The aim of the present work was to develop a new whole in vitro high throughput method to predict drug rate and extent of access across the BBB. The system permits estimation of fu,plasma, Vu,brain and Kp,uu,brain in a single experimental system, using in vitro cell monolayers in different condition…

MaleSwineChemistryHigh-throughput screeningDrug delivery to the brainAlbuminBrainPharmaceutical ScienceModels TheoreticalPharmacologyBlood–brain barrierIn vitroCell LineDogsDrug Delivery Systemsmedicine.anatomical_structureBlood-Brain BarrierIn vivoCell cultureDrug DiscoverymedicineAnimalsMolecular MedicineAnimal studiesMolecular Pharmaceutics
researchProduct

BRAIN-TARGETED SOLID LIPID NANOPARTICLES CONTAINING RILUZOLE: PREPARATION, CHARACTERIZATION AND BIODISTRIBUTION

2009

Aim: Developments within nanomedicine have revealed a great potential for drug delivery to the brain. In this study nanoparticulate systems as drug carriers for riluzole, with sufficiently high loading capacity and small particle size, were prepared to a reach therapeutic drug level in the brain. Materials & method: Solid lipid nanoparticles containing riluzole have great potential as drug-delivery systems for amyotrophic lateral sclerosis and were produced by using the warm oil-in-water microemulsion technique. The resulting systems obtained were approximately 88 nm in size and negatively charged. Drug-release profiles demonstrated that a drug release was dependent on medium pH. Biodi…

Maleamyotrophic lateral sclerosisBiodistributionMaterials scienceSOLID LIPID NANOPARTICLES BRAIN TARGETING RILUZOLEBiomedical EngineeringDrug delivery to the brainMedicine (miscellaneous)NanoparticleBioengineeringDevelopmentPharmacologyRats Sprague-DawleyPlasmaDrug StabilitySolid lipid nanoparticlemedicineAnimalsHumansGeneral Materials ScienceParticle Sizebiodistributionmodified releaseDrug CarriersRiluzoleBrainLipidsRiluzoleRatssolid lipid nanoparticlesNeuroprotective AgentsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoNanomedicineNanoparticlesParticle sizeDrug carriermedicine.drug
researchProduct

SUPRAMOLECULAR ASSOCIATION OF RECOMBINANT HUMAN GROWTH HORMONE WITH HYDROPHOBIZED POLYHYDROXYETHYLASPARTAMIDES

2008

Abstract The protein delivery properties of polymer supramolecular assemblies were investigated by using recombinant human growth hormone (rh-GH) and two polyhydroxyethylaspartamide (PHEA) derivatives: (a) PHEA-C 16 obtained by PHEA random grafting with hexadecylalkylamine; (b) PHEA-PEG 5000 -C 16 obtained by PHEA random co-grafting with hexadecylalkylamine and 5 kDa poly(ethylene glycol). The two polymers possessed similar self-assembling properties: critical micelle concentration (CMC) and particle size. The protein loading (protein/polymer, w/w, %) was 12.1 ± 1.3% and 8.5 ± 0.4% with PHEA-C 16 and PHEA-PEG 5000 -C 16 , respectively. The rh-GH/polymer association constant calculated by Sc…

Malechemistry.chemical_classificationHuman Growth HormoneSupramolecular chemistryPharmaceutical ScienceGeneral MedicinePolymerProtein delivery supramolecular assembly growth hormone polyhydroxyethylaspartamideDissociation (chemistry)Polyethylene GlycolsRatsSupramolecular assemblychemistry.chemical_compoundDrug Delivery SystemschemistryPolymer ratioCritical micelle concentrationAnimalsOrganic chemistryPeptidesDrug carrierEthylene glycolCells CulturedBiotechnologyNuclear chemistry
researchProduct

Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre

2018

Abstract Background One of the most important vulnerabilities falling the efficacy of recombinant human growth hormone (r-hGH) treatment is low adherence especially in young patients. This study was planned to describe the correlation between r-hGH treatment efficacy and adherence in real-life setting using easypod™. Methods Forty patients younger than 18 years, affected by a clinical condition in which r-hGH is available and treated with r-hGH easypod™, were enrolled in a retrospective, observational, real-world data, monocentric trial. The study design provided the retrospective collection of records collected by a questionnaire proposed to the patients and their parents and compared with…

Malemedicine.medical_specialtyAdolescentTreatment adherenceInjections SubcutaneousTurner syndrome030209 endocrinology & metabolismSelf AdministrationInjections SubcutaneouGrowth hormone deficiencyMedication Adherence03 medical and health sciencesEasypod™0302 clinical medicinePatient satisfactionDrug Delivery SystemsGrowth DisorderRetrospective StudieInternal medicineTurner syndromemedicineHumansTreatment adherence030212 general & internal medicineChildGrowth DisordersRetrospective StudiesR-hGHbusiness.industryHuman Growth HormoneResearchlcsh:RJ1-570Retrospective cohort studylcsh:PediatricsSmall for gestational ageRecombinant Proteinmedicine.diseaseRecombinant ProteinsPatient SatisfactionChild PreschoolPediatrics Perinatology and Child HealthSmall for gestational ageObservational studyFemaleGrowth hormone deficiencybusinessSelf-administrationDrug Delivery SystemHumanItalian Journal of Pediatrics
researchProduct

N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: In vivo study with TNBS-induced colitis model in rats

2011

5-Aminosalicylic acid (5-ASA) loaded N-Succinyl-chitosan (SucCH) microparticle and freeze-dried system were prepared as potential delivery systems to the colon. Physicochemical characterization and in vitro release and swelling studies were previously assessed and showed that the two formulations appeared to be good candidates to deliver the drug to the colon. In this work the effectiveness of these two systems in the treatment of inflammatory bowel disease was evaluated. In vitro mucoadhesive studies showed excellent mucoadhesive properties of both the systems to the inflamed colonic mucosa. Experimental colitis was induced by rectal instillation of 2,4,6-trinitrobenzene sulfonic acid (TNB…

Malemedicine.medical_specialtyAminosalicylic acidColonPolymersPharmaceutical ScienceLymphocyte ActivationInflammatory bowel diseaseGastroenterologyAbsorptionChitosanchemistry.chemical_compoundDrug Delivery SystemsIn vivoInternal medicinemedicineAnimalsIntestinal MucosaRats WistarMicroparticleColitisMesalaminePeroxidaseChitosanDrug CarriersChemistryAnti-Inflammatory Agents Non-SteroidalOrgan SizeColitismedicine.diseasedigestive system diseasesIn vitroRatsDisease Models AnimalFreeze DryingTrinitrobenzenesulfonic AcidSwellingmedicine.symptomInternational Journal of Pharmaceutics
researchProduct

Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients.

2012

Abstract Purpose The aim of our study was to assess the results and cost of a treatment strategy involving transarterial chemoembolisation with drug eluting beads (DEB-TACE) in patients with unresectable non-metastatic hepatocellular carcinoma (HCC). Patients and methods This study included all patients treated with DEB-TACE in our hospital between January 2009 and December 2010. All patients received DEB-TACE on demand and were evaluated after each session. Results Twenty-one patients received an average of 1.3 sessions. The median time to treatment discontinuation and median progression-free survival was 181 days and 295 days, respectively. Toxicity caused treatment discontinuation in thr…

Malemedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaCostResultDrug Delivery SystemsTransarterial chemoembolisationOn demandmedicineHumansRadiology Nuclear Medicine and imagingIn patientChemoembolization TherapeuticAgedRetrospective StudiesAged 80 and overRadiological and Ultrasound TechnologyDrug eluting beadsbusiness.industryLiver NeoplasmsGeneral MedicineDirect costMiddle Agedmedicine.diseaseDrug eluting beadsMicrospheresSurgeryDiscontinuationTreatment OutcomeMedian timeHepatocellular carcinomaCosts and Cost AnalysisFemaleProspective payment systembusinessDiagnostic and interventional imaging
researchProduct

Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol \textless70 mg/dL During 5 Years After Ischemic Stroke

2020

Background and Purpose— The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature or aortic arch plaque >4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results …

Malemedicine.medical_specialtyStatinTime Factorsmedicine.drug_class[SDV]Life Sciences [q-bio]Brain IschemiaLDLchemistry.chemical_compoundDrug Delivery SystemsEzetimibeInternal medicinemedicineClinical endpointHumansangiographyMyocardial infarctionStrokeAgedAdvanced and Specialized NursingCerebral infarctionCholesterolbusiness.industryAnticholesteremic Agentsinformed consentcholesterolCholesterol LDLMiddle Agedmedicine.diseaseEzetimibestroke[SDV] Life Sciences [q-bio]aortachemistryNumber needed to treatCardiologyFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct